Your browser doesn't support javascript.
loading
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights.
Sujit, Sheeba J; Aminu, Muhammad; Karpinets, Tatiana V; Chen, Pingjun; Saad, Maliazurina B; Salehjahromi, Morteza; Boom, John D; Qayati, Mohamed; George, James M; Allen, Haley; Antonoff, Mara B; Hong, Lingzhi; Hu, Xin; Heeke, Simon; Tran, Hai T; Le, Xiuning; Elamin, Yasir Y; Altan, Mehmet; Vokes, Natalie I; Sheshadri, Ajay; Lin, Julie; Zhang, Jianhua; Lu, Yang; Behrens, Carmen; Godoy, Myrna C B; Wu, Carol C; Chang, Joe Y; Chung, Caroline; Jaffray, David A; Wistuba, Ignacio I; Lee, J Jack; Vaporciyan, Ara A; Gibbons, Don L; Heymach, John; Zhang, Jianjun; Cascone, Tina; Wu, Jia.
Afiliación
  • Sujit SJ; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Aminu M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Karpinets TV; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen P; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Saad MB; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Salehjahromi M; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Boom JD; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qayati M; Department of Biomedical Engineering, Duke University, Durham, NC, USA.
  • George JM; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allen H; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Antonoff MB; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
  • Hong L; Natural Sciences, Rice University, Houston, TX, USA.
  • Hu X; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heeke S; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tran HT; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Le X; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Elamin YY; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Altan M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vokes NI; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sheshadri A; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin J; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lu Y; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Behrens C; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Godoy MCB; Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chang JY; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chung C; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jaffray DA; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wistuba II; Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JJ; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vaporciyan AA; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gibbons DL; Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Heymach J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cascone T; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wu J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Commun ; 15(1): 3152, 2024 Apr 11.
Article en En | MEDLINE | ID: mdl-38605064
ABSTRACT
While we recognize the prognostic importance of clinicopathological measures and circulating tumor DNA (ctDNA), the independent contribution of quantitative image markers to prognosis in non-small cell lung cancer (NSCLC) remains underexplored. In our multi-institutional study of 394 NSCLC patients, we utilize pre-treatment computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) to establish a habitat imaging framework for assessing regional heterogeneity within individual tumors. This framework identifies three PET/CT subtypes, which maintain prognostic value after adjusting for clinicopathologic risk factors including tumor volume. Additionally, these subtypes complement ctDNA in predicting disease recurrence. Radiogenomics analysis unveil the molecular underpinnings of these imaging subtypes, highlighting downregulation in interferon alpha and gamma pathways in the high-risk subtype. In summary, our study demonstrates that these habitat imaging subtypes effectively stratify NSCLC patients based on their risk levels for disease recurrence after initial curative surgery or radiotherapy, providing valuable insights for personalized treatment approaches.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido